Professor of Medicine, Mt. Auburn Hospital
Cardiology
Dr. Victor Gurewich, MD
|
|
Give Review
Victor Gurewich is an expert in the field of Cardiology. He researched medicine at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1 in research and 12 in primary care medicine Victor Gurewich, MD is a published MD as well. He has 100 publications published. The latest was: Evidence for the expression of urokinase-type plasminogen activator by human venous endothelial cells in vivo. Victor Gurewich accepts all Medicare patients.
Publications
- Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement.
- Highly Effective Fibrinolysis by a Sequential Synergistic Combination of Mini-Dose tPA plus Low-Dose Mutant proUK.
- Urokinase-type plasminogen activator up-regulates its own expression by endothelial cells and monocytes via the u-PAR pathway.
- Catalytic and fibrinolytic properties of recombinant urokinase plasminogen activator from E. coli, mammalian, and yeast cells.
- Fibrinolysis: an unfinished agenda.
- Evidence for the expression of urokinase-type plasminogen activator by human venous endothelial cells in vivo.
- Managed care ethics.
- A comparison of recombinant urokinase with vascular surgery for acute arterial occlusion of the legs.
- Truth or consequences.
- Intra-arterial pro-urokinase in ischemic stroke.
- Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and endothelial cells.
- Analysis of the forces which stabilize the active conformation of urokinase-type plasminogen activator.
- An efficient system for production of recombinant urokinase-type plasminogen activator.
- Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator.
- Identification of a flexible loop region (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity.
- A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.
- Preparation of single-stranded phagemid DNA without chromosomal DNA contamination.
- Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen.
- The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension.
- Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits?
- Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes.
- Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture.
- Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction.
- Substrate inhibition of fibrin-dependent plasminogen activation by tissue-type plasminogen activator.
- Coronary rethrombosis after successful thrombolysis.
- Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis.
- The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator.
- Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator.
- Lipoprotein(a) in coronary heart disease. Is it a risk factor after all?
- Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin.
- Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis.
- Inactivation of the intrinsic activity of pro-urokinase by diisopropyl fluorophosphate is reversible.
- Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
- A pilot study of pro-urokinase in the treatment of deep vein thrombosis.
- Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
- Transfemoral temporary pacing and deep vein thrombosis.
- Fibrin degradation products and impedance plethysmography. Measurements in the diagnosis of acute deep vein thrombosis.
- Lower molecular weight fibrinogen and non-clottable fibrinogen derivatives in diabetes mellitus.
- High-density lipoproteins and atherosclerosis.
- The value of measuring percent high-density lipoprotein in assessing risk of cardiovascular disease.
- Exercise-induced fibrinolysis--fact not fiction.
- Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
- The antithrombotic effect of aspirin and dipyridamole in relation to prostaglandin synthesis.
- Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine.
- Pulmonary embolism after ligation of the inferior vena cava.
- Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism.
- Pathogenesis of venous thrombosis in relation to its prevention by dextran and heparin.
- Humoral factors in massive pulmonary embolism: an experimental study.
- Epinephrine potentiation of platelet aggregation: its effect on death from experimental pulmonaryeembolism.
- Streptokinase for chronic arterial occlusive disease.
- Streptokinase in acute pulmonary embolism.
- Some guidelines for heparin therapy of venous thromboembolic disease.
- Detection of intravascular coagulation by a serial-dilution protamine sulfate test.
- Passive flexion and femoral vein flow: a study using a motorized foot mover.
- Laboratory identification of intravascular coagulation. The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products.
- Thrombolysis with streptokinase in rabbits. Dose response, fibrin-clot specificity and laboratory evaluation of fibrinolytic effect.
- Letter: The fibrinogenolytic pathway of fibrinogen catabolism: additional comments.
- The role of fibrin monomer and an in vivo thrombin-induced-anticoagulant in experimental venous thrombosis.
- Letter: Heparin, aspirin and Lee-White clotting time.
- Letter: Ethanol gelation and protamine sulfate. Comparison and critique.
- Intravascular coagulation during pregnancy and the puerperium.
- The laboratory diagnosis of venous thromboembolic disease by measurement of fibrinogen-fibrin degradation products and fibrin monomer.
- Pulmonary thromboembolism.
- The resistance of soluble derivatives of fibrinogen and the sensitivity of its insouble forms to fibrinolytic degradation in blood.
- Letter: Causes of a negative ethanol gelation test in diffuse intravascular coagulation.
- Excercise-induced fibrinolytic activity and its effect on the degradation of fibrinogen, fibrin and fibrin-like precipitates.
- The effect of heparin and dipyridamole on the deposition of fibrin-like material in rabbits infused with soluble fibrin monomer or fibrinogen.
- The organ distribution of 125I-fibrin in the generalized Shwartzman reaction and its relation to leucocytes.
- The fate of soluble fibrin monomer in relation to intravascular fibrin formation and degradation in rabbits.
- Isolation and characterization of an in vivo thrombin-induced anticoagulant activity.
- Letter: Heparin dosage and clotting time.
- Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components.
- Reduction of platelet serotonin and the response to pulmonary emboli.
- Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test.
- Letter: Haemostasis, fibrinolysis, and deep-vein thrombosis.
- Peripheral venous scanning with 125 I-tagged fibrinogen.
- Thrombolytic therapy for acute myocardial infarction.
- Biological properties of recombinant and of natural pro-urokinase.
- Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase).
- Lipids, lipoproteins, fibrinogen and fibrinolytic activity in angiographically assessed coronary heart disease.
- Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary ...
- Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.
- Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
- Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this ef...
- Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase).
- A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-se...
- Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
- Fibrin activatable urokinase (FA-UK): a latent form of UK found in urine related to a complex with an inhibitor/fibrin-interacting cofactor.
- Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of l...
- Activation of fibrin-bound plasminogen by pro-urokinase and its complementariness with that by tissue plasminogen activator.
- Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
- Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experim...
- Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro...
- Thrombospondin forms complexes with single-chain and two-chain forms of urokinase.
- The pH dependence of the binding of pro-urokinase to fibrin/celite.
- Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myo...
- A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
- The effect of the carboxy-terminal lysine of urokinase on the catalysis of plasminogen activation.
- Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminoge...
Schools
Harvard Medical School
Beth Israel Hospital
West Roxbury Va Hospital
Doctors Specialties
- Internal Medicine
- Cardiology
Accepted Insurances
- Aetna
- Blue Card PPO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Harvard Pilgrim Health Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tufts Health Plans
- Tufts PPO
- UniCare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Beth Israel Deaconess Medical Center -
Harvard Medical School
Hospital
-
Mount Auburn Hospital
Drug Facts
| NPI NUMBER | 1306825799 | |
| NPPES Provider LastName | GUREWICH | |
| NPPES Provider FirstName | VICTOR | |
| NPPES Provider ZIPCode | 021385600 | |
| NPPES Provider State | MA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 896.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306825799 |
| Last Name Of The Provider | GUREWICH |
| First Name Of The Provider | VICTOR |
| View All |
Similar Doctors
|
|
Dr. Leonard M. Zir, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marion P. Hogan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shadi G. Miri, MD |
|
|
Dr. Andreea M. Bujor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Simon S. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark M. Friedman, MD |
|
|
Dr. Joseph S. Wong, MD |
|
|
Dr. Robert Spencer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leila Ganjehei, MD |
|
|
Dr. Michael T. Chin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deepak Thatai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nadine E. Palermo, DO |
|
|
Dr. Sandra J. Wang, MD
This Doctor is OpenDoctor Recommended.
|